Details of the Drug

General Information of Drug (ID: DMA4LNE)

Drug Name

SGN-LIV1A

Synonyms

Ladiratuzumab Vedotin

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 2	[1]
Small-cell lung cancer	2C25.Y	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody drug conjugate

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 39 member 6 (SLC39A6)	TTZN1CF	S39A6_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Non-small-cell lung cancer

ICD Disease Classification

2C25

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Solute carrier family 39 member 6 (SLC39A6)	DTT	SLC39A6	3.54E-08	0.26	0.25

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
2	SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.